AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Biodesix Validates Thermo Fisher's Oncomine Dx Express Test for Solid Tumors on Genexus Dx Integrated Sequencer.
ByAinvest
Tuesday, Aug 19, 2025 9:49 am ET1min read
Biodesix has been recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS diagnostics. The company recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer. This designation reflects Biodesix's expertise in molecular diagnostics and NGS testing capabilities. Biodesix Development Services will contribute to the development of diagnostic tests and tools, aiming to improve cancer diagnosis and care.
Biodesix, Inc. (Nasdaq: BDSX), a leader in personalized diagnostics, has been recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS diagnostics. This designation reflects Biodesix's expertise in molecular diagnostics and NGS testing capabilities [1].The company recently validated Thermo Fisher's tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer. This achievement underscores Biodesix's role in the development and validation of diagnostic tools crucial for cancer research and treatment [2].
Biodesix Development Services will contribute to the development of diagnostic tests and tools, aiming to improve cancer diagnosis and care. The company's collaboration with Thermo Fisher is part of a broader initiative to advance NGS-based diagnostics and precision medicine [1].
Scott Hutton, CEO at Biodesix, expressed his excitement about the designation, stating, "Being a member of Thermo Fisher’s COE network puts us in excellent company with other global groups committed to transforming cancer diagnosis and care. We are excited about the potential to offer the Oncomine Dx Express Test in the future" [1].
Upcoming presentations will provide more information on the Thermo Fisher NGS precision oncology solution and Biodesix's application of this technology for industry clients and healthcare professionals [1].
References:
[1] https://www.stocktitan.net/news/BDSX/biodesix-recognized-as-a-thermo-fisher-scientific-center-of-l4w8ty9i7iz1.html
[2] https://www.globenewswire.com/news-release/2025/08/19/3135801/0/en/Biodesix-Recognized-as-a-Thermo-Fisher-Scientific-Center-of-Excellence-COE-for-NGS-Diagnostics.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet